> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Federal Register Corrected on Kadom Pharma ANDAs
- URL: https://www.fdaweb.com/federal-register-corrected-on-kadom-pharma-andas/
- Published: 2020-09-28T12:00:00.000Z
- Updated: 2026-09-14T16:30:28.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147745

*Federal Register* notice: FDA is correcting a notice that appeared in the 7/21 *Federal Register* announcing the withdrawal of approval of 10 abbreviated new drug applications (ANDAs) from multiple applicants. Two ANDAs from Kadmon Pharmaceuticals (ribavirin capsules and tablets) are now not being withdrawn because the company timely informed FDA that it did not want the approval of the ANDAs withdrawn. To view the notice, click [here](https://s3.amazonaws.com/public-inspection.federalregister.gov/2020-21456.pdf?ref=fdaweb.com).